ikefageze.blogspot.com
The Journal’s report cites “people familiar with the Both companies declined to commentr tothe newspaper. The report comes a day after Glaxko (NYSE: GSK) announced that Viehbacher, the company’s head of Nortgh American pharmaceuticals, would be leaving the compant “to pursue another opportunity.” Viehbacher is givint up a package of morethan $4 million offered to him late in 2007 after the company chose another internal candidate, European pharmaceuticals boss Andrew to replace Jean-Pierre Garnier as Glaxo' CEO.
The Journal’s report doesn’t specify what positiob Viehbacher might take with which sells medicinesincludinyg Allegra, Ambien and Plavin in the Uniter States. Viehbacher is based in ResearcjTriangle Park, where GlaxoSmithKline employs more than 5,000o people. The company has headquarters in
No comments:
Post a Comment